Skip To Main Content
Anna Repesh on Muck Rack

Anna Repesh

As seen in: Science Magazine, BioRxiv, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Anna Repesh’s profile

Articles by Anna Repesh

The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion

|
By Lan Wang, Chris Harris, Crissy Dudgeon, Orjola Prela, Juliana Cazares de Menezes, Ching-Hua Shih, Christina Davidson, Anthony S Casabianca, Subhajyoti De, Wade Narrow, Jennifer Becker, Paul M. Grandgenett, Michael A Hollingsworth, Jean L. Grem, Minsoo Kim, Yeonsun Hong, Scott Gerber, Paula M. Vertino, Zachary L Klamer, Anna Repesh, Yansheng Hao, Allison Ryan, Anna Bianchi, Jashodeep Datta, Brian J. Altman, Brian B. Haab, Darren Carpizo, Chongfeng Gao, Mitchell Breitenbach
| Cell Press Verified
Keywords pancreatic ductal adenocarcinoma immune evasion antigen presentation Dec2 cancer dormancy circadian rhythm sTRA mouse model resectable PDAC Introduction Metastatic recurrence following surgery with curative intent is a major clinical problem in oncology. Latent recurrences arise from disseminating tumor cells (DTCs) that are occult at the time of surgery and remain dormant for years before reactivating to form tumors.
Open in Who Shared Issue with article?

Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples

|
By Braelyn Binkowski, Zachary L Klamer, Chong Gao, Ben Staal, Anna Repesh, David M. Brass, Pamela Bartlett, Steven Gallinger, Maria Blomqvist, Chanjuan Shi, Aatur D Singhi, Randall E Brand, Ying Huang, Hoang-Le Tran, J. Bradley Morrow, Galen Hoste, Peter Allen Verified
| Science Magazine Verified
Open in Who Shared Issue with article?

Multiplexed Glycan Immunofluorescence Identification of Pancreatic Cancer Cell Subpopulations in Both Tumor and Blood Samples

|
By Zachary L Klamer, Ben Staal, Braelyn Binkowski, Anna Repesh
| BioRxiv
Abstract Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays suitable for early disease detection that would improve patient outcomes. The CA19-9 glycan is currently used as a standalone biomarker for PDAC. Furthermore, previous studies have shown that cancer cells may display aberrant membrane-associated glycans. We therefore hypothesized that PDAC cancer cell subpopulations could be distinguished by aberrant glycan signatures.
Open in Who Shared Issue with article?
Show More